Physician profile
Daniel S Shue
NPI 1487974473
$3,200.23
in general payments reported to CMS, 2019-2025
17 companies · $760 in 2025
The $760 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $166 · 2021: $263 · 2022: $543 · 2023: $406 · 2024: $449 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,595 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,594.52 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $842.03 | 2019-2025 | Skyrizi, Rinvoq |
| Boston Scientific Corporation | $460.36 | 2019-2023 | Exalt Model D |
| Gilead Sciences, INC. | $283.86 | 2019-2025 | |
| Janssen Biotech, INC. | $243.47 | 2019-2025 | Tremfya, Stelara |
| Merck Sharp & Dohme LLC | $181.52 | 2021-2024 | Dificid |
| Celgene Corporation | $180.02 | 2022-2023 | Zeposia |
| Redhill Biopharma INC. | $144.77 | 2020-2022 | |
| Cook Medical LLC | $135.00 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2022 | |
| Intercept Pharmaceuticals, INC. | $116.06 | 2021-2025 | |
| Pfizer INC. | $115.35 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.66 | 2020-2023 | Entyvio |
| Olympus America INC. | $100.00 | 2025 | Disposable Distal Attachment, Endoclot Sis, Olympus |
| Ipsen Biopharmaceuticals, INC | $54.03 | 2024-2025 | Iqirvo, Bylvay |
| Genzyme Corporation | $48.72 | 2022-2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $46.51 | 2019-2024 | Sutab, Suflave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.88 | 2024 | Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Shue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.